[go: up one dir, main page]

AR127893A1 - Terapia del cáncer dirigida a egfr - Google Patents

Terapia del cáncer dirigida a egfr

Info

Publication number
AR127893A1
AR127893A1 ARP220103358A ARP220103358A AR127893A1 AR 127893 A1 AR127893 A1 AR 127893A1 AR P220103358 A ARP220103358 A AR P220103358A AR P220103358 A ARP220103358 A AR P220103358A AR 127893 A1 AR127893 A1 AR 127893A1
Authority
AR
Argentina
Prior art keywords
egfr
targetting
cancer therapy
component
tipiracil
Prior art date
Application number
ARP220103358A
Other languages
English (en)
Inventor
Athanasios Pallis
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR127893A1 publication Critical patent/AR127893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una combinación que comprende (a) un componente de anticuerpos anti-EGFR que comprende uno o dos anticuerpos anti-EGFR o porciones de unión a antígeno de los mismos y (b) un componente de trifluridina / tipiracilo.
ARP220103358A 2021-12-10 2022-12-07 Terapia del cáncer dirigida a egfr AR127893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21306751 2021-12-10

Publications (1)

Publication Number Publication Date
AR127893A1 true AR127893A1 (es) 2024-03-06

Family

ID=80035092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103358A AR127893A1 (es) 2021-12-10 2022-12-07 Terapia del cáncer dirigida a egfr

Country Status (3)

Country Link
AR (1) AR127893A1 (es)
TW (1) TW202339796A (es)
WO (1) WO2023105051A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69629156T2 (de) 1995-03-29 2004-05-06 Taiho Pharmaceutical Co. Ltd. Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CN101675075B (zh) 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
MX2013010444A (es) * 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
DK3042669T3 (da) * 2013-09-06 2023-06-12 Taiho Pharmaceutical Co Ltd Antitumormiddel og forstærker af antitumorvirkning
US20200347140A1 (en) * 2017-08-30 2020-11-05 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies

Also Published As

Publication number Publication date
WO2023105051A1 (en) 2023-06-15
TW202339796A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
CL2023002105A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
CL2020003223A1 (es) Anticuerpos il-11
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
CL2020003218A1 (es) Anticuerpos dirigidos contra il-11ra
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
JOP20200268A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
MX2022006078A (es) Terapias de combinacion para el tratamiento del cancer.
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
MX2022000137A (es) Composiciones de anticuerpos para la ruptura de biopelículas.
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
CO2023002034A2 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
MX2024000563A (es) Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
MX2022001022A (es) Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
JOP20210144A1 (ar) أجسام مضادة للبيريوستين واستخداماتها
AR127893A1 (es) Terapia del cáncer dirigida a egfr

Legal Events

Date Code Title Description
FB Suspension of granting procedure